One of the timeliest and, some say controversial, topics in clinical cardiac electrophysiology today is the proper role of the implantable cardioverter-defibrillator (ICD) in the treatment of patients ...
Background: Although more than 150,000 implantable cardioverter defibrillators (ICDs) are implanted yearly worldwide, only few studies systematically examined complications of ICD therapy in large ...
The indications for ICD implantation continue to expand; however, these devices are associated with complications related to the implantation procedure itself and morbidity caused by the normal and ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced that a cardiac resynchronization therapy defibrillator and an implantable cardioverter ...
The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing ...
A standard test of the implantable cardioverter defibrillator (ICD) is linked to significant thought-processing problems that improve for most patients within a year after the device is inserted, ...
The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins. The FDA has approved the Aurora Extravascular Implantable ...
First-of-its-kind Aurora EV-ICD™ system offers single device, single procedure with lead placed outside of heart and veins FDA approval of the Medtronic Aurora EV-ICD system includes the system's ...
Medtronic has secured an FDA green light for a new type of implantable cardioverter-defibrillator that the medtech giant describes as the first of its kind. Unlike other ICDs that are wired into ...
A wearable automatic defibrillator may be an alternative to an implantable cardiac defibrillator for a small group of patients, say researchers. There are few large, randomized and controlled clinical ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter ...